{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:07:10Z","timestamp":1790554030520,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014484","name":"Psyadon Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ymgme.2016.02.005","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T02:08:02Z","timestamp":1455934082000},"page":"401-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease"],"prefix":"10.1016","volume":"117","author":[{"given":"Tanya","family":"Khasnavis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sommerfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Nyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chipkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3969","authenticated-orcid":false,"given":"H.A.","family":"Jinnah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.02.005_bb0005","series-title":"Manual for ASEBA School-Age Forms & Profiles","author":"Achenbach","year":"2001"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0010","series-title":"Manual for ASEBA Adult Forms & Profiles","author":"Achenbach","year":"2003"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF02172213","article-title":"Self-injury in Lesch-Nyhan disease","volume":"24","author":"Anderson","year":"1994","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01058150","article-title":"Cognitive abilities of patients with Lesch-Nyhan disease","volume":"22","author":"Anderson","year":"1992","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0025","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0030","first-page":"353","article-title":"Dopamine deficiency in self-injurious behavior","volume":"25","author":"Breese","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0361-9230(90)90240-Z","article-title":"A dopamine deficiency model of Lesch-Nyhan disease-the neonatal-6-OHDA-lesioned rat","volume":"25","author":"Breese","year":"1990","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0091-3057(84)80110-0","article-title":"Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome","volume":"21","author":"Breese","year":"1984","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresrev.2004.08.004","article-title":"The neonate 6-hydroxydopamine lesioned rat: a model for clinical neuroscience and neurobiological principles","volume":"48","author":"Breese","year":"2004","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0050","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-3565(25)13263-1","article-title":"Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity","volume":"247","author":"Chipkin","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0055","first-page":"95","article-title":"Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by l-dopa is related to D1 dopamine receptors","volume":"7","author":"Criswell","year":"1992","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF02246069","article-title":"Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia","volume":"121","author":"Den Boer","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0065","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1056\/NEJM199606133342403","article-title":"Presynaptic dopaminergic deficits in Lesch-Nyhan disease","volume":"334","author":"Ernst","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0070","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1074\/jbc.M111.317701","article-title":"Genotype-phenotype correlations in Lesch-Nyhan disease: moving beyond the gene","volume":"287","author":"Fu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0075","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/brain\/awt202","article-title":"Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder","volume":"137","author":"Fu","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","article-title":"A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome","volume":"37","author":"Gilbert","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ana.24191","article-title":"Loss of neurotransmitter phenotype among midbrain dopamine neurons in Lesch-Nyhan disease","volume":"76","author":"Goettle","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mdc3.12040","article-title":"Consequences of delayed dental extraction in Lesch-Nyhan disease","volume":"1","author":"Goodman","year":"2014","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0095","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/0278-5846(90)90090-4","article-title":"Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis","volume":"14","author":"Gualtieri","year":"1991","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s002130100725","article-title":"Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans","volume":"155","author":"Haney","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awq013","article-title":"Attenuated variants of Lesch-Nyhan disease","volume":"133","author":"Jinnah","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/awl056","article-title":"Delineation of the motor disorder of Lesch-Nyhan disease","volume":"129","author":"Jinnah","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF02246067","article-title":"Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02246068","article-title":"Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000071464","article-title":"Self-biting induced by activation of L-type calcium channels in mice: dopaminergic influences","volume":"25","author":"Kasim","year":"2003","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000095113","article-title":"The role of dopamine receptors in the neurobehavioral syndrome provoked by activation of L-type calcium channels in mice","volume":"28","author":"Kasim","year":"2006","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0002-9343(64)90104-4","article-title":"A familial disorder of uric acid metabolism and central nervous system function","volume":"36","author":"Lesch","year":"1964","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1469-8749.1995.tb15017.x","article-title":"Cognitive functioning in Lesch-Nyhan syndrome","volume":"37","author":"Matthews","year":"1995","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1469-8749.2010.03786.x","article-title":"A population study of Lesch-Nyhan disease in the United Kingdom","volume":"53","author":"McCarthy","year":"2011","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s002130100724","article-title":"Repeated administration of the D1\/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine","volume":"155","author":"Nann-Vernotica","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0155","series-title":"AAMR Adaptive Behavior Scale - Residential and Community Examiner's Manual","author":"Nihira","year":"1993"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01543464","article-title":"Behavior in the Lesch-Nyhan syndrome","volume":"6","author":"Nyhan","year":"1976","journal-title":"J. Autism Child. Schizophr."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0145445500242003","article-title":"A review of behavioral treatments used for Lesch-Nyhan syndrome","volume":"24","author":"Olson","year":"2000","journal-title":"Behav. Modif."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1469-8749.2003.tb00925.x","article-title":"Modes and patterns of self-mutilation in persons with Lesch-Nyhan disease","volume":"45","author":"Robey","year":"2003","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1023\/A:1013299028321","article-title":"The behavior problems inventory: an instrument for the assessment of self-injury, stereotyped behavior, and aggression\/destruction in individuals with developmental disabilities","volume":"31","author":"Rojahn","year":"2001","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0180","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1212\/WNL.0000000000001128","article-title":"Brain white matter volume abnormalities in Lresch-Nyhan disease and its variants","volume":"84","author":"Schretlen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0185","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1474-4422(13)70238-2","article-title":"Cross-sectional analyses of regional brain volume abnormalities in Lesch-Nyhan disease and its variants","volume":"12","author":"Schretlen","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1017\/S135561770177703X","article-title":"Neurocognitive functioning in Lesch-Nyhan disease and partial hypoxanthine-guanine phosphoribosyltransferase deficiency","volume":"7","author":"Schretlen","year":"2001","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0195","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0012162205001374","article-title":"Behavioral aspects of Lesch-Nyhan disease and its variants","volume":"47","author":"Schretlen","year":"2005","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/1098-2779(200102)7:1<3::AID-MRDD1002>3.0.CO;2-#","article-title":"Self-injurious behavior: gene, brain, behavior relationships","volume":"7","author":"Schroeder","year":"2001","journal-title":"Mental Retard Dev Disabil Res Rev"},{"key":"10.1016\/j.ymgme.2016.02.005_bb0205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0165-0173(99)00094-6","article-title":"Lesch-Nyhan syndrome and the basal ganglia","volume":"32","author":"Visser","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ymgme.2016.02.005_bb0210","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1073\/pnas.93.11.5539","article-title":"Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo","volume":"93","author":"Wong","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:01:06Z","timestamp":1748782866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216300178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1096719216300178"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.02.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}